Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study [Original Articles]

Conclusions:
Proportional reductions in Lp(a) were dependent on apolipoprotein(a) isoform size. Taking this into account, the likely benefits of niacin–laropiprant on coronary risk through Lp(a) lowering are small. Novel therapies that reduce high Lp(a) levels by at least 80 nmol/L (40%) may be needed to produce worthwhile benefits in people at the highest risk because of Lp(a).

Clinical Trial Registration:
URL: https://clinicaltrials.gov. Unique identifier: NCT00461630.

Source: Circulation: Cardiovascular Genetics - February 15, 2018 Category: Cardiology Authors: Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., Landray, M., Armitage, J., on behalf of the HPS2-THRIVE Collaborative Group Tags: Lipids and Cholesterol, Cardiovascular Disease, Genetics, Treatment Original Articles Source Type: research